G
Gail H. Vance
Researcher at Indiana University
Publications - 111
Citations - 17822
Gail H. Vance is an academic researcher from Indiana University. The author has contributed to research in topics: Fluorescence in situ hybridization & Cytogenetics. The author has an hindex of 34, co-authored 107 publications receiving 16209 citations. Previous affiliations of Gail H. Vance include College of American Pathologists & University of Utah.
Papers
More filters
Journal ArticleDOI
American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Allred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria to be monitored.
Journal ArticleDOI
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C. Wolff,M. Elizabeth H. Hammond,David G. Hicks,Mitch Dowsett,Lisa M. McShane,Kimberly H. Allison,D. C. Allred,John M. S. Bartlett,Michael Bilous,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Pamela B. Mangu,Soonmyung Paik,Edith A. Perez,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Daniel F. Hayes +19 more
TL;DR: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive).
Journal ArticleDOI
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff,M. Elizabeth H. Hammond,David G. Hicks,Mitch Dowsett,Lisa M. McShane,Kimberly H. Allison,D. C. Allred,John M. S. Bartlett,Michael Bilous,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Pamela B. Mangu,Soonmyung Paik,Edith A. Perez,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Daniel F. Hayes +19 more
TL;DR: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive).
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C. Wolff,M. Elizabeth H. Hammond,Jared N. Schwartz,Karen L. Hagerty,D. Craig Alfred,Richard J. Cote,Mitchell Dowsett,Patrick L. Fitzgibbons,Wedad Hanna,Amy S. Langer,Lisa M. McShane,Soonmyung Paik,Mark D. Pegram,Edith A. Perez,Michael F. Press,Anthony Rhodes,Catharine M. Sturgeon,Sheila E. Taube,Raymond R. Tubbs,Gail H. Vance,Marc J. van de Vijver,Thomas M. Wheeler,Daniel F. Hayes +22 more
TL;DR: A testing algorithm that relies on accurate, reproducible assay performance, including newly available types of brightfield ISH, is proposed and strongly recommends validation of laboratory assay or modifications, use of standardized operating procedures, and compliance with new testing criteria are recommended.
Journal ArticleDOI
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
Jay P. Patel,Mithat Gonen,Maria E. Figueroa,Hugo Fernandez,Zhuoxin Sun,Janis Racevskis,Pieter Van Vlierberghe,Igor Dolgalev,Sabrena Thomas,Olga Aminova,Kety Huberman,Janice Cheng,Agnes Viale,Nicholas D. Socci,Adriana Heguy,Athena M. Cherry,Gail H. Vance,Rodney R. Higgins,Rhett P. Ketterling,Robert E. Gallagher,Mark R. Litzow,Marcel R.M. van den Brink,Hillard M. Lazarus,Jacob M. Rowe,Selina M. Luger,Adolfo A. Ferrando,Elisabeth Paietta,Martin S. Tallman,Ari Melnick,Omar Abdel-Wahab,Ross L. Levine +30 more
TL;DR: Genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, are identified and the significance of these predictors in an independent cohort is validated.